Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.

MLA

Castillo, Jorge J., et al. “Ibrutinib and Venetoclax as Primary Therapy in Symptomatic, Treatment-Naïve Waldenström Macroglobulinemia.” Blood, vol. 143, no. 7, Feb. 2024, pp. 582–91. EBSCOhost, https://doi.org/10.1182/blood.2023022420.

APA

Castillo, J. J., Branagan, A. R., Sermer, D., Flynn, C. A., Meid, K., Little, M., Stockman, K., White, T., Canning, A., Guerrera, M. L., Kofides, A., Liu, S., Liu, X., Richardson, K., Tsakmaklis, N., Patterson, C. J., Hunter, Z. R., Treon, S. P., & Sarosiek, S. (2024). Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia. Blood, 143(7), 582–591. https://doi.org/10.1182/blood.2023022420

Chicago

Castillo, Jorge J, Andrew R Branagan, David Sermer, Catherine A Flynn, Kirsten Meid, Megan Little, Katherine Stockman, et al. 2024. “Ibrutinib and Venetoclax as Primary Therapy in Symptomatic, Treatment-Naïve Waldenström Macroglobulinemia.” Blood 143 (7): 582–91. doi:10.1182/blood.2023022420.